Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs

Oncogene volume 28, pages S4–S13 (2009)Cite this article

Abstract

Non-small-cell lung cancer (NSCLC) is a major global health problem and is the leading cause of cancer death worldwide. Current treatment involves nonspecific, nonselective cytotoxic chemotherapy, which results in only a modest increase in survival and causes significant toxicity to the patient. Targeted agents are initially effective in certain small subpopulations of patients, but eventually nearly all patients become resistant to further treatment. The limitations in efficacy and safety associated with available treatments for NSCLC underscore the need for novel agents with improved efficacy and safety profiles. This review discusses the limitations of currently recommended therapies for patients with advanced NSCLC and discusses new agents in clinical development for this disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM . (2003). SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471–478.

    Article  CAS  PubMed  Google Scholar 

  • Adams JM, Cory S . (2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324–1327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Avastin® (bevacizumab) prescribing information (2008). Genentech, Inc, South San Francisco, CA. Available at: http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. Accessed 19 September 2008.

  • Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494–6501.

    Article  CAS  PubMed  Google Scholar 

  • Bazley LA, Gullick WJ . (2005). The epidermal growth factor receptor family. Endocr Relat Cancer 12 (Suppl 1): S17–S27.

    Article  CAS  PubMed  Google Scholar 

  • Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A et al. (2007). Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 25: 2727–2734.

    Article  CAS  PubMed  Google Scholar 

  • Brandes JC, Grossman SA, Ahmad H . (2006). Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Invest 24: 283–287.

    Article  CAS  PubMed  Google Scholar 

  • Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR et al. (2001). Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19: 1734–1742.

    Article  CAS  PubMed  Google Scholar 

  • Britten CD . (2004). Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 3: 1335–1342.

    CAS  PubMed  Google Scholar 

  • Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam YZ et al. (2007). Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25: 394s (ASCO Annual Meeting Proceedings Part I), abstract 7539. Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&conFID=47&abstractID=31939. Accessed 22 July 2009.

    Article  Google Scholar 

  • Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C et al. (1993). High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091–3096.

    CAS  PubMed  Google Scholar 

  • Carney DN . (2002). Lung cancer—time to move on from chemotherapy. N Engl J Med 346: 126–128.

    Article  PubMed  Google Scholar 

  • Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L et al. (2006). Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 7: 389–394.

    Article  CAS  PubMed  Google Scholar 

  • Crawford J, Dale DC, Lyman GH . (2004). Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100: 228–237.

    Article  PubMed  Google Scholar 

  • Dole M, Nuñez G, Merchant AK, Maybaum J, Rode CK, Bloch CA et al. (1994). Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54: 3253–3259.

    CAS  PubMed  Google Scholar 

  • Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH . (2005). Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. J Support Oncol 3: 149–154.

    PubMed  Google Scholar 

  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900–5909.

    Article  CAS  PubMed  Google Scholar 

  • Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O et al. (2005). Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65: 1770–1777.

    Article  CAS  PubMed  Google Scholar 

  • Engelman JA, Jänne PA . (2008). Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895–2899.

    Article  PubMed  Google Scholar 

  • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T et al. (2007). PF00299804, an irreversible pan-ErbB inhibitor, is effective in lung cancer models with EGFR and ErbB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924–11932.

    Article  CAS  PubMed  Google Scholar 

  • Eskens F, Mom CH, Planting AST, Gietema JA, Amelsberg A, Huisman H et al. (2008). A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98: 80–85.

    Article  CAS  PubMed  Google Scholar 

  • Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D et al. (2006). Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24: (ASCO Annual Meeting Proceedings Part I), abstract 7001.

  • Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W et al. (2007). Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 13: 3713–3723.

    Article  CAS  PubMed  Google Scholar 

  • Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e313.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C et al. (2007). Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 12: 191–200.

    Article  CAS  PubMed  Google Scholar 

  • Haber DA, Settleman J . (2005). Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle 4: 1057–1059.

    Article  CAS  PubMed  Google Scholar 

  • Habib AA, Chun SJ, Neel BG, Vartanian T . (2003). Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. Mol Cancer Res 1: 219–233.

    CAS  PubMed  Google Scholar 

  • Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J et al. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589–1597.

    Article  CAS  PubMed  Google Scholar 

  • Herbst RS, Ansari RH, Gorbunova V, Manikhas G, Saleh M, Boyd T et al. (2007). Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC): B1-06. J Thorac Oncol 2: S335.

    Article  Google Scholar 

  • Herbst RS, Frankel SR . (2004). Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 10: 4245S–4248S.

    Article  CAS  PubMed  Google Scholar 

  • Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE et al. (2007). Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 25 (Suppl): abstract no. 7544 395s.

    Google Scholar 

  • Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U et al. (2008). BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774–4782.

    Article  CAS  PubMed  Google Scholar 

  • Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC et al. (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18: 752–760.

    Article  CAS  PubMed  Google Scholar 

  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J et al. (2007). Phase II clinical trial of chemotherapy-naive patients > or =70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25: 760–766.

    Article  CAS  PubMed  Google Scholar 

  • Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM et al. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184–2191.

    Article  CAS  PubMed  Google Scholar 

  • Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM et al. (2001). Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210–3218.

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792.

    Article  CAS  PubMed  Google Scholar 

  • Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M et al. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764–5769.

    Article  CAS  PubMed  Google Scholar 

  • Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGFR receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al. (2008). Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366–377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G et al. (2008). Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3979–3986.

    Article  CAS  PubMed  Google Scholar 

  • Marks PA, Richon VM, Rifkind RA . (2000). Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210–1216.

    Article  CAS  PubMed  Google Scholar 

  • Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD et al. (2007). KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13: 2890–2896.

    Article  CAS  PubMed  Google Scholar 

  • Metro G, Finocchiaro G, Cappuzzo F . (2006). Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Ann Oncol 17 (Suppl 2): ii42–ii45.

    Article  PubMed  Google Scholar 

  • Miller VA, Wakelee HA, Lara PN, Cho J, Chowhan NM, Pennell I et al. (2008). Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial. J Clin Oncol 26 (Suppl): abstract 8028.

    Article  Google Scholar 

  • Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A et al. (2006). Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24: 552–562.

    Article  CAS  PubMed  Google Scholar 

  • Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY . (2007). Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13: 2795–2803.

    Article  CAS  PubMed  Google Scholar 

  • Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM et al. (2005). A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3: 9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mross KB, Gmehling D, Frost A, Baas F, Strecker R, Hennig J et al. (2005). A clinical, phase I pharmacokinetic (PK) and pharmacodynamic study of twice-daily BIBF 1120 in advanced cancer patients. J Clin Oncol 23 (Suppl 16): abstract 3031.

    Article  Google Scholar 

  • Natale RB, Bodkin D, Govindan R, Sleckman B, Rizvi N, Capo A et al. (2006). ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 24 (Suppl): abstract no. 7000 364s.

    Google Scholar 

  • National Comprehensive Cancer Network (2008). Clinical Practice Guidelines: Non-small Cell Lung Cancer v.2. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed 19 September 2008.

  • Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J et al. (2006). Phase II study of Lucanixâ„¢ a transforming growth factor β2 (TGF-β2) antisense gene modified allogeneic tumor cell vaccine in non small cell lung cancer. Mol Ther 13 (Suppl 1): S424–S425; abstract no. 1104.

    Article  Google Scholar 

  • O’Brien ME, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, Von Pawel J et al. (2004). SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 15: 906–914.

    Article  PubMed  Google Scholar 

  • Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S et al. (2007). Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18: 317–323.

    Article  CAS  PubMed  Google Scholar 

  • Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.

    Article  PubMed  PubMed Central  Google Scholar 

  • Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K et al. (2008). FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26 (Suppl): abstract 3.

    Article  Google Scholar 

  • Riely GJ, Politi KA, Miller VA, Pao W . (2006). Update on epidermal growth factor receptor mutations in non–small cell lung cancer. Clin Cancer Res 12: 7232–7241.

    Article  CAS  PubMed  Google Scholar 

  • Rizvi N, Kris M, Miller V, Azzoli C, Krug L, Bekele S et al. (2007). A phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations: P3-136. J Thorac Oncol 2 (Suppl 4): S737.

    Article  Google Scholar 

  • Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC et al. (2008). Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19: 362–369.

    Article  CAS  PubMed  Google Scholar 

  • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. (2006). Paclitaxel-carboplatin alone or with bevcizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S et al. (2002). Phase III randomized trial comparing three platinum-based doublets in advanced non–small-cell lung cancer. J Clin Oncol 20: 4285–4291.

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C et al. (2008a). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer. J Clin Oncol 26: 3543–3551.

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti G, von Pawel J, Reck M, Cupit L, Cihon F, DiMatteo S et al. (2008b). Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) Trial. J Thorac Oncol (European Lung Cancer Conference) 3 (4 Suppl 1): S9–S98; Late-breaking abstract 2750.

    Google Scholar 

  • Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98.

    Article  CAS  PubMed  Google Scholar 

  • Sharma SV, Bell DW, Settleman J, Haber DA . (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169–181.

    Article  CAS  PubMed  Google Scholar 

  • Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.

    Article  CAS  PubMed  Google Scholar 

  • Shih JY, Gow CH, Yang PC . (2005). EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med 353: 207–208.

    Article  CAS  PubMed  Google Scholar 

  • Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP et al. (2008). Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650–656.

    Article  CAS  PubMed  Google Scholar 

  • Stinchcombe TE, Socinski MA . (2008). Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 (Suppl 1): 28–36.

    Article  CAS  PubMed  Google Scholar 

  • Tabernero J . (2007). The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5: 203–220.

    Article  CAS  PubMed  Google Scholar 

  • Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J et al. (2005). Gefitinib plus BSC in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537.

    Article  CAS  PubMed  Google Scholar 

  • Tsao M, Zhu C, Sakurada A, Chang I, Whitehead M, Kamei-Keid S et al. (2006). An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol 24 (18S): (ASCO Annual Meeting Proceedings Part I), abstract 7005.

  • van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D et al. (2007). EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 18: 99–103.

    Article  CAS  PubMed  Google Scholar 

  • Von Pawel J, Kaiser R, Eschbach C, Stefanie M, Love J, Gatzemeier U, Reck M . (2007). A double blind phase II study of BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25 (Suppl 18): abstract no. 7635 418s.

    Google Scholar 

  • Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA . (2008). Erlotinib for advanced non–small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 2350–2357.

    Article  CAS  PubMed  Google Scholar 

  • Wissner A, Mansour TS . (2008). The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim) 341: 465–477.

    Article  CAS  Google Scholar 

  • Yang C, Shih J, Chao T, Tsai C, Su W, Hsia T et al. (2008). Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: preliminary results of a single-arm phase II clinical trial. J Clin Oncol 26: abstract 8026.

    Article  Google Scholar 

  • Ye D, Mendelsohn J, Fan Z . (1999). Augmentation of a humanized anti-HER2 mAb4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18: 731–738.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The author thanks Johnathan C Maher, PhD, of BlueSpark Healthcare for medical and editorial assistance in this paper. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals.

Author information

Authors and Affiliations

  1. Sarah Cannon Research Institute, Nashville, TN, USA

    H A Burris III

Authors
  1. H A Burris III
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H A Burris III.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burris, H. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 28 (Suppl 1), S4–S13 (2009). https://doi.org/10.1038/onc.2009.196

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.196

Keywords

Search

Advanced search

Quick links